Struggling Intercell replaces its CEO

After stumbling badly in the clinic, Austria's Intercell announced that CEO Gerd Zettlmeissl has abruptly resigned and been replaced by COO Thomas Lingelbach. Late last year shares of Intercell AG, the last of the independent vaccine makers, cratered after the company announced that it was forced to toss its late-stage vaccine patch project for travelers' diarrhea on the scrap heap after a pair of clinical trials flunked their primary endpoints. The trial failure triggered a company-wide restructuring. Intercell release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.